The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study

European Child and Adolescent Psychiatry

Volumn 26, Issue 1, 2017, Pages 35-46

  Baeza, Inmaculada ^a,e   Vigo, Laura ^c   de la Serna, Elena ^a,e   Calvo Escalona, Rosa ^a,e   Merchán Naranjo, Jessica ^d   Rodríguez Latorre, Pamela ^d   Arango, Celso ^d   Castro Fornieles, Josefina ^a,b,e  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Adolescents; Antipsychotic; Children; Side effects; Weight gain

Indexed keywords

ADIPONECTIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GHRELIN; HOMOCYSTEINE; HORMONE; HYPNOTIC AGENT; INSULIN; LEPTIN; MOOD STABILIZER; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; THYROTROPIN; THYROXINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADOLESCENT; ADOLESCENT OBESITY; ARTICLE; AUTISM; BIPOLAR DISORDER; BODY HEIGHT; BODY MASS; BODY WEIGHT DISORDER; CHILD; CHILD PSYCHIATRY; CHILDHOOD OBESITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HOSPITALIZATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; THYROTROPIN BLOOD LEVEL; TIC; WEIGHT GAIN; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; MULTICENTER STUDY; OBESITY; PHYSIOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GHRELIN; HOMOCYSTEINE; HUMANS; INSULIN; LEPTIN; MALE; OBESITY; PROSPECTIVE STUDIES; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84969785033     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-016-0866-x     Document Type: Article

References (60)

1. Baeza I, De la Serna E, Calvo-Escalona R, Morer A, Merchán-Naranjo J, Tapia C, Martínez-Cantarero MC, Andrés P, Alda JA, Sánchez B, Arango C, Castro-Fornieles J (2014) Antipsychotic use in children and adolescents. A 1-year follow-up study. J Clin Psychopharmacol 5:613–619
2. Olfson M, Blanco C, Liu SM, Wang S, Correll CU (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69:1247–1256
3. Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621–645
4. Arango C (2015) Present and future of developmental neuropsychopharmacology. Eur Neuropsychopharmacol 25:703–712
5. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765–1773
6. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A (2006) Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 16:308–316
7. Safer DJ (2004) A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429–436
8. Martínez-Ortega JM, Funes-Godoy S, Díaz-Atienza F, Gutiérrez-Rojas L, Pérez-Costillas L, Gurpegui M (2013) Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 22:457–479
9. Cohn TA, Sernyak MJ (2006) Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51:492–501
10. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696
11. Deng C, Weston-Green K, Huang X (2010) The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 34:1–4
12. Baptista T (1999) Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 100:3–16
13. Cuerda C, Velasco C, Merchán-Naranjo J, García-Peris P, Arango C (2014) The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. Eur J Clin Nutr 68:146–152
14. Havel PJ (2001) Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med (Maywood). 226:963–977
15. Friedman JM (2002) The function of leptin in nutrition, weight, and physiology. Nutr Rev 60:S1–14 (discussion S68–84, 85–87)
16. Sentissi O, Epelbaum J, Olié JP, Poirier MF (2008) Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schiz Bull 34:1189–1199
17. Barsh GS, Schwartz MW (2002) Genetic approaches to studying energy balance: perception and integration. Nat Rev Genet 3:589–600
18. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198
19. Lucidi P, Murdolo G, Di Loreto C, Parlanti N, De Cicco A, Ranchelli A, Fatone C, Taglioni C, Fanelli C, Santeusanio F, De Feo P (2004) Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. J Endocrinol Invest 27:RC12–5
20. Heilbronn LK, Smith SR, Ravussin E (2003) The insulin-sensitizing role of the fat derived hormone adiponectin. Curr Pharm Des 9:1411–1418
21. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinmia. J Clin Endocrinol Metab 86:1930–1935
22. Reinehr T (2010) Obesity and thyroid function. Mol Cel Endocrinol 316:165–171
23. Reinehr T (2011) Thyroid function in the nutritionally obese child and adolescent. Curr Opin Pediatrics 23:415–420
24. Aypak C, Türedi O, Yüce A, Görpelioğlu S (2013) Thyroid-stimulating hormone (TSH) level in nutritionally obese children and metabolic co-morbidity. J Pediatr Endocrinol Metab 26:703–708
25. Jacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F (2005) Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol 62:487–491
26. Roef G, Lapauw B, Goemaere S, Zmierczak HG, Toye K, Kaufman JM, Taes Y (2012) Body composition and metabolic parameters are associated with variation in thyroid hormone levels among euthyroid young men. Eur J Endocrinol 167:719–726
27. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D (2013) Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 1:CD006612. doi:10.1002/14651858.CD006612.pub3
28. Karatela RA, Sainani GS (2009) Plasma homocysteine in obese, overweight and hypertensive subjects in Mumbai. Indian Heart 61:156–159
29. Vayá A, Carmona P, Badia N, Pérez R, Hernandez Mijares A, Corella D (2011) Homocysteine levels and the metabolic syndrome in a Mediterranean population: a case-control study. Clin Hemorheol Microcirc 47:59–66
30. Yakub M, Schulze KJ, Khatry SK, Stewart CP, Christian P, West KP Jr (2014) High Plasma Homocysteine increases risk of metabolic syndrome in 6–8 year old children in rural Nepal. Nutrients 6:1649–1661
31. Jin H, Meyer JM, Mudaliar S, Jeste DV (2008) Impact of atypical antipsychotic therapy on leptin, ghrelin and adiponectin. Schiz Res 100:70–85
32. Palik E, Birkas KD, Faludi G, Karádi I, Cseh K (2005) Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 68(suppl 1):S60–S64
33. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Terán JM, Carrasco-Marín E, Mata I, Crespo-Facorro B (2008) Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol 28:289–295
34. Basoglu C, Oner O, Gunes C, Semiz UB, Ates AM, Algul A, Ebrinc S, Cetin M, Ozcan O, Ipcioglu O (2010) Plasma orexin A, ghrelin, cholecistokinin, visfasin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int Clin Psychopharmacol 25:165–171
35. Richards AA, Hickman IJ, Wang AY, Jones AL, Newell F, Mowry BJ, Whitehead JP, Prins JB, Macdonald GA (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 26:232–237
36. Sporn AL, Bobb AJ, Gogtay N, Stevens H, Greenstein DK, Clasen LS, Tossell JW, Nugent T, Gochman PA, Sharp WS, Mattai A, Lenane MC, Yanovski JA, Rapoport JL (2005) Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 44:925–933
37. Maayan LA, Vakhrusheva J (2010) Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Human Psychopharmacol 25:133–138
38. Martin A, Scahill L, Anderson G, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125–1127
39. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA (2009) Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adol Psychopharmacol 19:101–109
40. Merchan-Naranjo J, Tapia C, Bailón C, Moreno C, Baeza I, Calvo-Escalona R, Morer A, Martínez-Cantarero C, Nestares PA, Alda JÁ, Muñoz D, Arango C (2012) Secondary effects of antipsychotic treatment in naïve or quasi-naïve children and adolescents: design of a follow-up protocol and baseline results. Rev Psiquiatr Salud Ment 5:217–228
41. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67:255–262
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
43. Sobradillo B, Aguirre A, Aresti U, Bilbao C, Fernández-Ramos A, Lizarraga H, Lorenzo L, Madariaga I, Rica I, Ruiz E, Sánchez C Santamaría, Serrano JM, Zabala A, Zurimendi B, Hernández M (2004) Curvas y tablas de crecimiento: estudios longitudinal y transversal. Fundación Faustino Orbegozo Eizaguirre, Bilbao
44. Flodmark CE, Lissau I, Moreno LA, Pietrobelli A, Widhalm K (2004) New insights into the field of children and adolescents’ obesity: the European perspective. Int J Obes Relat Metab Disord 28:1189–1196
45. Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA, Martínez-Cantarero C, Moreno C, de Andrés P, Cuerda C, de la Serna E, Correll CU, Fraguas D, Parellada M (2014) Second-generation antipsychotic use in children and adolescents; a 6-month prospective cohort study in drug-naïve patients. J Am Acad Child Adol Psychiatry 53:1179–1190
46. McIntyre RS, Jerrell JM (2008) Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 162:929–935
47. Faraone SV, Biederman J, Morley CP, Spencer TJ (2008) Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994–1009
48. Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU (2009) Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 19:563–573
49. Gentile S (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 10:527–542
50. Gonzaga NC, Medeiros CC, de Carvalho DF, Alves JG (2014) Leptin and cardiometabolic risk factors in obese children and adolescents. J Paediatr Child Health 50:707–712
51. Poveda E, Callas NE, Baracaldo CM, Castillo C, Hernández P (2007) Leptin levels in school age children associated with antropometric measurements and lipid profiles. Biomedica 27:505–514
52. Venner AA, Lyon ME, Doyle-Baker PK (2006) Leptin: a potencial biomarker for childhood obesity? Clin. Biochem 39:1047–1056
53. Karavani G, Strich D, Edri S, Gillis D (2014) Increases in thyrotropin within the near-normal range are associated with increased triiodothyronine but not increased thyroxine in the pediatric age. J Clin Endocrinol Metab 99(8):E1471–5. doi:10.1210/jc.2014-1441 (Epub 2014 May 30)
54. Marras V, Casini MR, Pilia S, Carta D, Civolani P, Porcu M, Uccheddu AP, Loche S (2010) Thyroid function in obese children and adolescents. Horm Res Paediatr 73:193–197
55. Margari L, Matera E, Craig F, Petruzzelli MG, Palmieri VO, Pastore A, Margari F (2013) Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol 28:177–183
56. Misiak B, Frydecka D, Laczmanski L, Slezak R, Kiejna A (2014) Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol. doi:10.1007/s00228-014-1762-2
57. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 13:27–35
58. Catli G, Anik A, Tuhan HÜ, Kume T, Bober E, Abaci A (2014) The relation of leptin and soluble leptin receptor levels with metabolic and clinical parameters in obese and healthy children. Peptides 56:72–76
59. Friedemann C, Heneghan C, Mahtani K, Thompson M, Perera R, Ward AM (2012) Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ 345:e4759. doi:10.1136/bmj.e4759
60. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adol Psychiatry 41:337–343